Literature DB >> 8096157

Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem.

J Benavides1, B Peny, D Ruano, J Vitorica, B Scatton.   

Abstract

Pharmacological characterization of [3H]benzodiazepine binding to membrane preparations of adult rat hippocampus and neonatal rat brain have demonstrated, in addition to the omega 1 and omega 2 populations of central omega benzodiazepine binding sites associated with GABAA receptors, the existence of binding sites with microM affinity for the imidazopyridines zolpidem and alpidem. In the present study we have investigated their comparative autoradiographic distribution using [3H]flumazenil as a ligand. In the neonatal rat CNS, the imidazopyridine derivatives zolpidem and alpidem were found to discriminate two [3H]flumazenil binding site populations with an IC50 value ratio of more than 200-fold. In the different regions investigated (spinal cord, striatum, neocortex and inferior colliculus) the low affinity component had IC50 values of 20-40 microM (zolpidem) and 5-15 microM (alpidem) and accounted for ca. 50% of the total binding site population. In the adult rat, these imidazopyridine derivatives displayed a greater displacing potency in the cerebellum (IC50 = 6 and 36 nM, respectively) than in the hippocampus (IC50 = 37 and 403 nM, respectively). In the cerebellum, [3H]flumazenil binding was fully displaced by 1 microM of either compound and Hill coefficients of displacement curves were close to unity. In the hippocampus, 25% of [3H]flumazenil binding were resistant to 3 microM zolpidem or 1 microM alpidem, but were displaced by 100 microM of either compound. CL 218,872 also displayed a greater displacing potency in the cerebellum (IC50 = 83 nM) than in the hippocampus (IC50 = 711 nM) but [3H]flumazenil binding in the hippocampus was fully displaced by 10 microM of this compound. In adult rat hippocampus, zolpidem and alpidem were found to discriminate between three central omega site subtypes which display high (IC50 = 31 and 6.1 nM, for these imidazopyridine derivatives. In contrast, CL 218,872 discriminated between omega 1 and omega 2 sites but not between two omega 2 receptor subpopulations. omega 1 sites were mainly localized in layer IV of the sensorimotor cortex, cerebellum, substantia nigra, olfactory bulb and inferior colliculus. omega 2I sites were present in the cortical mantle (with higher levels in the cingulate and olfactory than in the sensorimotor cortex) and in subcortical (hippocampus, hypothalamus and nucleus accumbens) limbic structures. In the hippocampus, hypothalamus, spinal cord and nucleus accumbens, omega 2L sites accounted for more than 25% of the specific [3H]flumazenil binding; the density of these sites was minor in the cortex and in most pyramidal and extrapyramidal system structures.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096157     DOI: 10.1016/0006-8993(93)90375-w

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment.

Authors:  Ravid Doron; Avital Sever; Assaf Handelsman; Roni Toledano; Motty Franko; Yafit Hirshler; Alon Shamir; Or Burstein; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2018-05-08       Impact factor: 3.444

Review 2.  Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships.

Authors:  Renê Oliveira Beleboni; Ruither Oliveira Gomes Carolino; Andrea Baldocchi Pizzo; Lissandra Castellan-Baldan; Joaquim Coutinho-Netto; Wagner Ferreira dos Santos; Norberto Cysne Coimbra
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

Review 3.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846.

Authors:  K E Vanover; J E Barrett
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

5.  Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.

Authors:  Enrique Sánchez-Lemus; Masaru Honda; Juan M Saavedra
Journal:  Behav Brain Res       Date:  2012-04-04       Impact factor: 3.332

6.  Benzodiazepine-GABAA receptor complex ligands in two models of anxiety.

Authors:  M Nazar; M Jessa; A Płaźnik
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 7.  Hypnosedative-induced complex behaviours : incidence, mechanisms and management.

Authors:  Christian R Dolder; Michael H Nelson
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  The effects of repeated zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: comparison with diazepam.

Authors:  Brittany T Wright; Catherine F Gluszek; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-15       Impact factor: 4.530

9.  Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety.

Authors:  Nunzio Denora; Valentino Laquintana; Angela Lopedota; Mariangela Serra; Laura Dazzi; Giovanni Biggio; Dhananjay Pal; Ashim K Mitra; Andrea Latrofa; Giuseppe Trapani; Gaetano Liso
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.580

10.  Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target.

Authors:  Takeshi Hiu; Zoya Farzampour; Jeanne T Paz; Eric Hou Jen Wang; Corrine Badgely; Andrew Olson; Kristina D Micheva; Gordon Wang; Robin Lemmens; Kevin V Tran; Yasuhiro Nishiyama; Xibin Liang; Scott A Hamilton; Nancy O'Rourke; Stephen J Smith; John R Huguenard; Tonya M Bliss; Gary K Steinberg
Journal:  Brain       Date:  2015-12-18       Impact factor: 13.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.